Sarepta Therapeutics (SRPT) Invested Capital (2010 - 2026)

Sarepta Therapeutics' Invested Capital history runs 17 years deep, the most recent figure standing at $2.3 billion for Q1 2026.

• In Q1 2026, Invested Capital rose 105.06% year-over-year to $2.3 billion; the TTM figure through Mar 2026 stood at $2.3 billion (up 105.06% YoY), while the FY2025 annual figure was $2.0 billion, down 26.09% from the prior year.
• Invested Capital was $2.3 billion for Q1 2026 at Sarepta Therapeutics, up from $2.0 billion in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $2.7 billion in Q4 2024 to a low of $1.1 billion in Q1 2025.
• Historically, Invested Capital has averaged $1.9 billion across 5 years, with a median of $2.0 billion in 2022.
• The sharpest annual moves came in 2025 and 2026: Invested Capital plunged 48.07% in 2025, then soared 105.06% in 2026.
• A 5-year view of Invested Capital shows it stood at $1.9 billion in 2022, then advanced by 8.71% to $2.1 billion in 2023, then rose by 27.06% to $2.7 billion in 2024, then fell by 26.09% to $2.0 billion in 2025, then advanced by 18.97% to $2.3 billion in 2026.
• The last three Invested Capital figures came in at $2.3 billion (Q1 2026), $2.0 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.